Search Results - "Ohigashi, An"

Synchronous multiple primary tumors in patients with malignant lymphoma: a retrospective study by Yagi, Yu, Kanemasa, Yusuke, Sasaki, Yuki, Ohigashi, An, Morita, Yuka, Tamura, Taichi, Nakamura, Shohei, Kageyama, Akihiko, Omuro, Yasushi, Shimoyama, Tatsu

“…Synchronous multiple primary malignant tumors (sMPMTs) are sometimes diagnosed in patients with malignant lymphoma. We herein investigated the prognostic…”
Get full text

Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy by Yagi, Yu, Kanemasa, Yusuke, Sasaki, Yuki, Goto, Sotaro, Yamamura, Yasuhiko, Masuda, Yusuke, Fujita, Kumiko, Ishimine, Kento, Hayashi, Yudai, Mino, Mano, Ohigashi, An, Morita, Yuka, Tamura, Taichi, Nakamura, Shohei, Okuya, Toshihiro, Matsuda, Shinichiro, Shimizuguchi, Takuya, Shingai, Naoki, Toya, Takashi, Shimizu, Hiroaki, Najima, Yuho, Kobayashi, Takeshi, Haraguchi, Kyoko, Doki, Noriko, Okuyama, Yoshiki, Shimoyama, Tatsu

“…Patients with refractory or relapsed (R/R) large B-cell lymphoma (LBCL) refractory to first-line chemotherapy or with early relapse have poor outcomes. While…”
Get full text

Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study by Yagi, Yu, Kanemasa, Yusuke, Sasaki, Yuki, Sei, Mina, Matsuo, Takuma, Ishimine, Kento, Hayashi, Yudai, Mino, Mano, Ohigashi, An, Morita, Yuka, Tamura, Taichi, Nakamura, Shohei, Okuya, Toshihiro, Shimizuguchi, Takuya, Shingai, Naoki, Toya, Takashi, Shimizu, Hiroaki, Najima, Yuho, Kobayashi, Takeshi, Haraguchi, Kyoko, Doki, Noriko, Okuyama, Yoshiki, Shimoyama, Tatsu

“…Abstract Objective The prognosis of patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) is poor. Although patients who fail…”
Get full text

P1153: UTILITY OF THE FRAILTY SCORE FOR PREDICTING PROGNOSIS AND INDIVIDUALIZING TREATMENT INTENSITY IN ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA by Yagi, Yu, Kanemasa, Yusuke, Sasaki, Yuki, Ishimine, Kento, Hayashi, Yudai, Mino, Mano, Ohigashi, An, Morita, Yuka, Tamura, Taichi, Nakamura, Shohei, Okuya, Toshihiro, Shimoyama, Tatsu

Get full text

Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma by Yagi, Yu, Kanemasa, Yusuke, Sasaki, Yuki, Okumura, Shunichi, Watanabe, Takako, Ishimine, Kento, Hayashi, Yudai, Mino, Mano, Ohigashi, An, Morita, Yuka, Tamura, Taichi, Nakamura, Shohei, Okuya, Toshihiro, Shimoyama, Tatsu

“…Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with a poor prognosis. The International Prognostic Index (IPI) and the…”
Get full text

A Case of Hormone Receptor‒Positive HER2‒Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant by Ishiguro, Atsushi, Tanimoto, Aya, Ito, Keiichiro, Ohigashi, An, Kato, Hiroaki, Abe, Masaru, Kubota, Reiko, Chiba, Ryohei, Matsunami, Osamu, Narita, Yoshiaki

“…A 58‒year‒post‒menoposal woman was presented with left chest pain and shortness of breath because her breast cancer metastasized to the skin, lung, and pleural…”
Get more information

Breast cancer information communicated on a public online platform : an analysis of 'Yahoo! Answer Japan' by Ohigashi, An

“…Notes Japan is a country with high use of Internet and online platforms for health information. Indicates 'Yahoo Answer Japan' is the most commonly used…”
Get full text

Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant by Morita, Yuka, Yagi, Yu, Kanemasa, Yusuke, Sasaki, Yuki, Ishimine, Kento, Hayashi, Yudai, Mino, Mano, Ohigashi, An, Tamura, Taichi, Nakamura, Shohei, Okuya, Toshihiro, Shimizuguchi, Takuya, Shingai, Naoki, Toya, Takashi, Shimizu, Hiroaki, Najima, Yuho, Kobayashi, Takeshi, Haraguchi, Kyoko, Doki, Noriko, Okuyama, Yoshiki, Ohashi, Kazuteru, Shimoyama, Tatsu

“…Pola-BR (polatuzumab vedotin, bendamustine, and rituximab) therapy received approval for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in Japan…”
Get more information

MO11-1 Efficacy and safety of perioperative dose-dense chemotherapy for breast cancer patients, including elderly population by Ishiguro, Atsushi, Tanimoto, Aya, Ito, Keiichiro, Ohigashi, An

Get full text

Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma by Morita, Yuka, Kanemasa, Yusuke, Sasaki, Yuki, Ohigashi, An, Tamura, Taichi, Nakamura, Shohei, Yagi, Yu, Kageyama, Akihiko, Omuro, Yasushi, Shimoyama, Tatsu

“…Maintaining relative dose intensity (RDI) of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the prognosis of patients…”
Get full text

P58-7 Aortitis after the use of granulocyte colony stimulating factors: A case of right lower gingival carcinoma by Watanabe, Masaya, Kanemasa, Yusuke, Morita, Yuka, Ohigashi, An, Tamura, Taichi, Nakamura, Shohei, Yagi, Yu, Kageyama, Akihiko, Shimoyama, Tatsu, Omuro, Yasushi

Get full text

MO33-1 Trends in chemotherapy at our hospital and department under the COVID-19 pandemic by Kageyama, Akihiko, Makino, Shinichiro, Ohigashi, An, Tamura, Taichi, Morita, Yuka, Nakamura, Shohei, Yagi, Yu, Kanemasa, Yusuke, Shimoyama, Tatsu, Omuro, Yasushi

Get full text

Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma by Yagi, Yu, Kanemasa, Yusuke, Sasaki, Yuki, Goto, Sotaro, Yamamura, Yasuhiko, Ishimine, Kento, Hayashi, Yudai, Mino, Mano, Ohigashi, An, Morita, Yuka, Tamura, Taichi, Nakamura, Shohei, Okuya, Toshihiro, Shimoyama, Tatsu

“…The optimal dose intensity of chemotherapy for elderly patients with diffuse large B cell lymphoma (DLBCL) remains controversial because of concerns about…”
Get full text

Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report by Yagi, Yu, Kanemasa, Yusuke, Ohigashi, An, Morita, Yuka, Tamura, Taichi, Nakamura, Shohei, Otsuka, Yuki, Kishida, Yuya, Kageyama, Akihiko, Shimizuguchi, Takuya, Toya, Takashi, Shimizu, Hiroaki, Najima, Yuho, Kobayashi, Takeshi, Haraguchi, Kyoko, Doki, Noriko, Okuyama, Yoshiki, Omuro, Yasushi, Shimoyama, Tatsu

“…Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality…”
Get full text